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Abstract
Background: Limitations of antifungal agents used in the treatment of oral candidiasis, as the development of
resistant strains, are known by the scientific community. In this context, the aim of this study was to evaluate the
antifungal activity of thymol against Candida albicans, Candida tropicalis and Candida krusei strains and to
determine its mode of action and synergistic effect when combined with the synthetic antifungal nystatin.
Methods: The minimum inhibitory concentration (MIC) was determined using a microdilution technique, and the
minimum fungicidal concentration (MFC) was determined via subculture sowing. The mode of action of thymol
was established by verifying fungal growth in the presence of sorbitol or ergosterol. The fractional inhibitory
concentration index (FIC) was determined using the checkerboard method.
Results: Thymol presented an antifungal effect, with MICs of 39 μg/mL for C. albicans and C. krusei and 78 μg/mL
for C. tropicalis. The results of the antifungal test remained unchanged in the presence of sorbitol; however, the MIC
value of thymol against C. albicans increased eight times (from 39.0 to 312.5 μg/mL) in presence of exogenous
ergosterol. The combination of thymol and nystatin reduced the MIC values of both products by 87.4 %, generating
an FIC index of 0.25.
Conclusions: Thymol was found to have a fungicidal effect on Candida species and a synergistic effect when
combined with nystatin.
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Background
The emergence of opportunistic fungal infections, espe-
cially in immunocompromised individuals, highlights the
need to elucidate new therapeutic options, especially be-
cause the microorganisms involved usually have remarkable
morphological plasticity and express genes involved in the
mechanisms of resistance to antifungal agents [1].
Oral candidiasis is a superficial infection that affects
the palate region and jugal mucosa. It is notable for its
high prevalence and the limited therapeutic tools
available for treatment. It is an infection produced by
microorganisms of the genus Candida; Candida albicans
is the most common and most pathogenic species [2–4],
although Candida tropicalis and Candida krusei have im-
portant roles in the development of the disease [5, 6].
Local and systemic factors may predispose individuals
or trigger clinical cases of oral candidiasis. Such factors in-
clude saliva acidity, hyposalivation, nightly use of dental
prostheses, endocrine disorders, nutritional deficiencies,
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smoking, poor oral hygiene, immunosuppressive drug use
and radiotherapy and chemotherapy treatment of maxillo-
facial structures [7].
The use of nystatin to treat tissue injury has been
recommended [8], although other substances, such as
miconazole, fluconazole, and ketoconazole may be pre-
scribed instead [9–11]. However, indiscriminate use and
the small number of available antifungal agents have
promoted the development of resistant strains, especially
in immunocompromised individuals [12]. This fact justi-
fies the development of new therapies for use in clinical
practice [13, 14].
Among these new therapies, natural products stand
out; they are considered sources of bioactive molecules
with potential therapeutic applications in medicine and
dentistry [15, 16]. Many studies have been conducted on
the antifungal activity of natural products against
Candida species involved in fungal infections of the
oral cavity [17–19]. Natural products include essential
oils and their constituents [20, 21], which may belong
to several classes of compounds, but terpenes and
phenylpropenes are the most common [16].
The interest in isolated monoterpenes has grown over
the past years as a result of their pharmacological use.
This increase in interest is particularly true for thymol,
which is a known antimicrobial agent [22, 23]. The use
of individual components provides greater predictability,
allowing the minimization of adverse effects [24].
Thymol (2-isopropyl-5-methylphenol) is a phytocon-
stituent classified as a monoterpene [25]. It is the major-
ity phytoconstituent in the essential oil of thyme
(Thymus vulgaris) [24] and is a major component of the
essential oil of oregano (Origanum vulgare) [16]. Some
studies have shown that thymol has antiseptic, anti-
inflammatory, antioxidant and healing properties and a
broad spectrum of biological activity [26–28].
Previous studies have shown that the toxicity of thy-
mol, like that of any other substance, is directly related
to the concentration applied to cell cultures [29]. The
exposure of human fibroblasts to different concentra-
tions of thymol (25 to 100 μg/mL) revealed cell viability
above 96 % when at 24, 48 and 72 h [30]. The cytotoxic
activity (50 % lethal concentration) of thymol in U-937
human promonocytic cells was LC50 ≥ 400 μg/mL [31].
In this context, the present study investigated the anti-
fungal activity of thymol against C. albicans strains with
respect to growth inhibition, microbial death, mode of




The microbiological tests were performed at the Labora-
tory of Oral Microbiology, Tropical Medicine Center
(NUMETROP) - Center for Health Sciences, Federal
University of Paraiba, Paraiba, Brazil.
Microorganisms
The reference Candida spp. strains used in this study were
Dutch cultures from the Central Bureau voor Schimmel
(CBS; Fungi Culture Central Office): C. albicans CBS 562,
C. tropicalis CBS 94 and C. krusei CBS 573.
Test products
The phytoconstituent thymol provided by Quinarí®
(Ponta Grossa, Parana, Brazil) and the synthetic antifun-
gal nystatin (Sigma-Aldrich, St. Louis, USA) were used
in the in vitro assays. The thymol presented as a white
powder and was solubilized in 70°GL alcohol.
Minimum inhibitory concentration (MIC)
The MIC was determined using the microdilution tech-
nique. Ninety-six-well microtiter plates with a U-shaped
bottom were used (ALAMAR®, Diadema, São Paulo,
Brazil). Initially, 100 μL of Sabouraud Dextrose Broth
(SDB) (HIMEDIA®, Mumbai, India) was distributed in
the plate holes. Then, 100 μL of thymol solution was
transferred to the first well and serially diluted by trans-
ferring an aliquot of 100 μL from the most concentrated
well to the next cavity. Thus, thymol concentrations
from 5.000 μg/mL to 2.44 μg/mL were obtained. Finally,
100 μL of inoculum corresponding to each strain was
added to each cavity [32].
The inocula were prepared in 0.9 % saline, and the tur-
bidity of the fungal suspensions was compared with that
of the solution in tube 0.5 of the McFarland nephelomet-
ric scale, which corresponds to an inoculum of approxi-
mately 106 CFU/mL, and adjusted as needed. Then, the
suspension was diluted in SDB to obtain an inoculum
concentration of 103 CFU/mL [32].
Meanwhile, the viability of yeast strains (growth control)
and medium sterility were controlled. As a positive con-
trol, the synthetic antifungal nystatin was used. Through
serial dilution, nystatin concentrations from 1,000 μg/mL
to 0.48 μg/mL were obtained. As a negative control, 70°
GL alcohol was diluted in water in the same proportions
used for solubilization of thymol.
The test was performed in triplicate, and the microtiter
plates were incubated at 35 °C for 24 h. A visual reading
was performed to determine the MIC of thymol on yeast
strains. The formation of cell clumps (“buds”) on the bot-
toms of the wells was considered. Thus, the lowest test
product concentration that could visibly inhibit fungal
growth was considered the MIC [32].
To confirm the presence of viable microorganisms,
10 μL of TTC dye (2,3,5-triphenyl tetrazolium chloride)
was used. This dye reflects the activity of the dehydrogen-
ase enzymes involved in the process of cell respiration [33].
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Minimum fungicidal concentration (MFC)
After the MIC determination, aliquots of the concentra-
tion corresponding to the MIC and the two immediately
most concentrated concentrations (for the thymol-
treated cultures and the positive and negative controls)
were subcultured in Petri dishes containing Sabouraud
Dextrose Agar (SDA; HIMEDIA®, Mumbai, India) and
incubated at 35 °C for 48 h. The MFC was defined as
the lowest product concentration that prevented visible
growth; that is, the lowest concentration that was able to
kill the fungus [32].
The MFC/MIC ratio was calculated to determine
whether thymol has a fungistatic (MFC/MIC ≥ 4) or
fungicidal activity (MFC/MIC <4) [34].
Mode of action
The mode of action was tested to indicate whether the
antifungal activity of thymol involves a direct interaction
with the cell wall structure of C. albicans (via testing
with sorbitol) or with the ion permeability of the mem-
brane of this organism (via the test with ergosterol).
Test with sorbitol
The MIC of thymol in the presence sorbitol (an osmotic
protector) against C. albicans was determined using the
microdilution technique [32] in triplicate.
Initially, 100 μL of SDB was added to each well of the
microtiter plate. Subsequently, 100 μL of thymol solu-
tion was transferred to the first well and serially diluted
with the removal of an aliquot of 100 μL from the most
concentrated well to the subsequent cavity. Thymol
solution concentrations from 5.000 μg/mL to 2.44 μg/mL
were obtained. Then, 100 μL of fungal inoculum
(103 CFU/mL) prepared in SDB previously supplemented
with sorbitol (Sigma-Aldrich, St. Louis, USA) was
transferred to the wells for a final concentration of
0.8 M sorbitol in each well [35–37].
A microorganism control was created by placing
100 μg of SDB and 100 μg of the inoculum with sorbitol
(0.8 M) in each cavity. Sterility control was also per-
formed; 100 μg SDB with sorbitol (0.8 M) was placed in
a plate column without fungal suspension. The plates
were incubated at 35 °C and the results were read after
48 h and again after 7 days [35–37].
Test with ergosterol
To determine whether thymol interacts with ergosterol,
the MIC against C. albicans was determined using the
microdilution technique [32] in triplicate in the presence
and absence of exogenous ergosterol (Sigma-Aldrich,
St. Louis, USA).
First, 100 μL of SDB was added to each well of the mi-
crotiter plate. Then, 100 μL of thymol solution was trans-
ferred to the first well and serially diluted by transferring a
100 μL aliquot from the most concentrated well to the
next well. Thymol solution concentrations from 5.000 to
2.44 μg/mL were obtained. Subsequently, 100 μL of fungal
inoculum (103 CFU/mL) prepared in SDB previously
supplemented with ergosterol in concentrations of 100,
200 and 400 μg/mL was transferred to the wells [35, 37].
Nystatin was tested as a positive control, and yeast
growth and sterility were also controlled.
Synergism test: checkerboard method
The combined effect of the two substances (nystatin and
thymol) was determined using the checkerboard tech-
nique to derive the fractional inhibitory concentration
(FIC) index.
Test product solutions of certain concentrations
(determined by their respective MICs) were used. Initially,
100 μL of SDB was added to the wells. Then, 50 μL of
each test product at various concentrations (MIC x 8,
MIC x 4, MIC x 2, MIC, MIC ÷ 2, MIC ÷ 4, and MIC ÷ 8)
was added horizontally (thymol) and vertically (nystatin).
Finally, 10 μL of fungal inoculum of the tested strains was
added (103 CFU/mL). Growth and sterility controls were
also performed. The results were read visually, and fungal
growth was shown using TTC dye. The assay was per-
formed in triplicate, and the microplate was incubated for
48 h at 35 °C [38–40].
The FIC index was calculated as the sum of FICA +
FICB, where A is thymol and B is nystatin. FICA, in turn,
is calculated using the MICA combined/MICA alone
ratio, while FICB = the MICB combined/MICB alone
ratio. This index was interpreted as follows: synergism
(<0.5), additivity (0.5-1.0), indifference (>1) or antag-
onism (>4.0).
Results
MIC and MFC determination
The MIC and MFC values of thymol and nystatin
against Candida spp. are shown in Table 1. The vehicle
Table 1 Antifungal activity of thymol against Candida spp
Strain Thymol Nystatin
MIC MFC MIC/MFC MIC MFC MIC/MFC
(μg/mL) (μg /mL) ratio (μg/mL) (μg/mL) ratio
Candida
albicans








39.0 39.0 1 1.9 1.9 1
CBS 573
Notes: MIC Minimum inhibitory concentration, MFC Minimum
fungicidal concentration
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used in the thymol solution (70°GL alcohol), at the same
concentration found in the solution of lower concentra-
tion of thymol which promoted fungal growth inhibition,
was not effective, meaning that it did not interfere with
the MIC values of the tested product against yeasts. The
MIC/MFC ratio for thymol showed that it had a fungi-
cidal effect against all of the tested strains.
Mode of action of thymol
The results showed that the antifungal properties of thy-
mol are not related to the biosynthetic pathways of the cell
wall because the results of the antifungal test remained
unchanged in the presence of an osmotic protector (MIC
in presence of sorbitol: 39.0 μg/mL). In contrast, the MIC
value of thymol against C. albicans increased eight times
(39.0 to 312.5 μg/mL) in the presence of exogenous ergos-
terol (Fig. 1), which indicates that thymol appears to bind
to the ergosterol in the membrane, which increases ion
permeability and ultimately results in cell death. The same
mode of action was also observed for synthetic antifungal
nystatin, which was used as a positive control.
Synergism test
As a result of combining thymol with nystatin, a signifi-
cant reduction in the MIC values was observed. For both
products, the MIC reduction was 87.4 % for the three
Candida strains tested. The FIC index value was 0.25,
indicating a synergistic effect (FIC < 0.5) for this associ-
ation in relation to the growth inhibition of the tested
strains (Table 2).
Discussion
The high prevalence and severity of infections caused by
yeasts of the genus Candida, which can cause significant
morbidity and mortality in affected patients (usually hos-
pitalized), has encouraged investigations to elucidate
new therapeutic approaches to treat candidiasis [41].
Because the oral cavity includes Candida spp. in its nor-
mal microbiota and because this disease is considered an
opportunistic infection, is an important site of disease
development.
This study used the Candida species usually identified
in oral fungal infections. C. albicans is present in the
oral cavities of approximately 30 to 50 % of people. It is
among the most virulent species [42]; it is able to pro-
duce phospholipases and proteases that can destroy host
tissues [43], and it expresses genes that are responsible
for the cellular responses involved in invasive growth,
cell wall formation, adaptation to osmotic stress [4] and
resistance to currently available antifungal agents in the
form of efflux pumps [44, 45], changes in the drugs’ site
of action [46], and changes in the lipid composition of
the fungal plasma membrane, which prevent the drugs’
inflow into the cell [47].
C. tropicalis and C. krusei are also important patho-
gens that contribute to the development of the disease.
Strains that are resistant to available therapeutic agents
have begun to appear, and there has been an increasing
number of immunocompromised people and increas-
ingly frequent use of antifungal agents for treatment
and/or prophylaxis [48, 49].
Low thymol concentrations were needed to inhibit the
growth of Candida strains, and thymol’s fungicidal effect
is considered important for infection control because
the immune responses of the host are usually compro-
mised, making it difficult for affected patients to recover
their health. The anti-Candida effect promoted by thymol
has been reported in other studies [50, 51]. Previous stud-
ies have shown that thymol is able to significantly reduce
the number of viable C. albicans cells, reducing up to
82 % the biofilm mass formed by this microorganism [52].
The elucidation of the action mechanisms of agents
with pharmacological potential, whether of natural or
synthetic origin, contributes to the development of ra-
tional therapeutic approaches, particularly in terms of
infections caused by resistant microorganisms, which














Fig. 1 The effect of different concentrations of exogenous
ergosterol (100-400 μg / mL) on the MIC (minimum inhibitory
concentration) of thymol and nystatin against Candida albicans
Table 2 The MIC of thymol and nystatin, when used in
association, and their combined FIC index values
Strain MIC of thymol MIC of nystatin FIC Interpretation
(μg/mL) (μg/mL)
Candida albicans 4.88 0.24 0.25 Synergism
CBS 562
Candida tropicalis 9.76 0.24 0.25 Synergism
CBS 94
Candida krusei 4.88 0.24 0.25 Synergism
CBS 573
Note: MIC Minimum inhibitory concentration, FIC Fractional inhibitory
concentration index
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new drugs when the first-choice agent is not effective.
The results of this study suggest that thymol acts at the
level of the fungal plasma membrane by interfering with
the process of ergosterol biosynthesis, promoting in-
creased membrane permeability and causing the depletion
of components essential to fungal cell survival [23, 25].
Generally, terpenes, particularly monoterpenes such as
thymol, are characterized by the chemical formula
C10H16, which may be cyclic or branched. The chemical
configuration of these molecules gives them hydropho-
bic properties and allows them to deposit on the lipo-
philic structures of microorganisms such as the plasma
membrane; this deposition leads to increased permeabil-
ity with a consequent loss of the electrolytes essential to
cell survival [20]. Other action mechanisms may be
involved, such as the inhibition of spore germination,
fungal proliferation and cell respiration [53].
Natural products with intrinsic antimicrobial activity
or products that promote the activity of commonly used
antibiotic/antifungal agents may represent new ways to
combat multiresistant microorganisms and prevent the
contact of these microorganisms with synthetic products,
thus reducing the risk of selecting new or improved resist-
ance mechanisms [54]. Natural products may also be
combined with traditional antimicrobials to enhance the
antimicrobial activity of both [55].
According to the literature, there are scientific evi-
dences for the use of nystatin in the treatment of fungal
infections of the oral mucosa [56] and it has been indi-
cated, with advantages over the other antifungals, such
as topical use and less side effects [57]. However, fungal
resistance has been reported [57] and the association be-
tween synthetic and natural antifungal is an alternative
to reducing the dose required for the effect and may re-
duce undesired side effects and prevent the development
of resistance to antifungals [58].
In the laboratory tests performed to investigate the
antimicrobial activity of synthetic or natural agents, one
of the simplest and best known protocols is the checker-
board test, which provides a two-dimensional arrange-
ment of different concentrations of substances and allows
the calculation of the FIC, which necessary for assessing
the combination’s synergism, additivity, indifference or
antagonism [59].
To promote greater efficiency of thymol and nystatin
when used at lower concentrations, the association of
these substances was proposed, and synergistic effect
was observed, with reduction of 87.4 % of the concentra-
tions of both products in relation to the effect provided
when assessed separately.
There are several mechanisms involved in the syner-
gistic activity of antifungal agents: a) the inhibition of
different stages in the fungal intracellular pathways that
are essential for cell survival; b) increased penetration of
one antifungal agent resulting from the action of another
antifungal agent on the fungal cell membrane; c) the inhib-
ition of carrier proteins; and d) the simultaneous inhibition
of different cell targets [60]. The mechanism of combined
thymol and nystatin appears to involve the inhibition of
ergosterol formation as a result of the antifungal agents’
action on the different enzymes responsible for the biosyn-
thesis of ergosterol and/or because an increase in cell per-
meability allows the passage of one or both agents.
It is noteworthy that this is the first study that reports
the synergistic effect of combined thymol and nystatin
and its potential use to treat superficial infections in the
oral mucosa caused by Candida species. Therefore, the
findings described here encourage the development of
clinical trials to evaluate the efficacy of this combination
treatment.
Conclusions
From the results obtained, it was concluded that thymol
has fungicidal action against C. albicans, C. tropicalis
and C. krusei strains, and its effect is probably the result
of interference with the synthesis and/or presence of er-
gosterol in the plasma membrane. The combination of
thymol and nystatin had a synergistic effect for inhibit-
ing the growth of these strains.
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